Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-Macgregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. CantleyGordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences